Hæmatologisk Klinik Reserver datoen! The 7th Copenhagen CLL Meeting: Towards chemo-free treatment of CLL? Torsdag 18. september 2014: IDA Mødecenter (Ingeniørernes hus) Chairmen: Christian H. Geisler and Carsten U. Niemann 1300-1400 Registration; sandwich, tea, fruit, veggies. 1400-1415: Christian Geisler Introduction. The Jesper Jurlander Young Investigator Award Moving from chemotherapy to targeted treatment Session 1 Christian Geisler somatic mutations, stereotyped subsets and their 1415-1500: Kostas Stamatopoulos therapeutic consequences Current standard immunochemotherapy in fit and unfit CLL 1500-1530: Christian Geisler Coffee break: Buffet, fruit, 30 min Session 2 Carsten Niemann Towards Chemo-free therapy of CLL 1600-1645: Adrian Wiestner Current status of kinase inhibitors in CLL 1645-1730: Matthew Davids ABT-0199 in CLL: Current status 1730-1800: John Gribben Lenalidomide in CLL. Current status Curent status of antibodies for CLL: CD20, CD19, 22, 37, 52, 1800-1830: Anders Österborg others. 1830-1845: Carsten Niemann Concluding remarks 1900- 3-course seasonal dinner Tilmelding: DHS’ hjemmeside: www.hematology.dk (Søg på CLL meeting i søgefeltet) eller følg Evt. spørgsmål til Conference Coordinator O. Gotthardsen, mail: coordinator@cll-cph.dk Sponsoreret af Roche a/s
Hæmatologisk Klinik Reserver datoen! The 7th Copenhagen CLL Meeting: Towards chemo-free treatment of CLL? Torsdag 18. september 2014: IDA Mødecenter (Ingeniørernes hus) Chairmen: Christian H. Geisler and Carsten U. Niemann 1300-1400 Registration; sandwich, tea, fruit, veggies. 1400-1415: Christian Geisler Introduction. The Jesper Jurlander Young Investigator Award Session 1 Christian Geisler Moving from chemotherapy to targeted treatment 1415-1500: Kostas Stamatopoulos somatic mutations, stereotyped subsets and their therapeutic consequences 1500-1530: Christian Geisler Current standard immunochemotherapy in fit and unfit CLL Coffee break: Buffet, fruit, 30 min Session 2 Carsten Niemann Towards Chemo-free therapy of CLL 1600-1645: Adrian Wiestner Current status of kinase inhibitors in CLL 1645-1730: Matthew Davids ABT-0199 in CLL: Current status 1730-1800: John Gribben Lenalidomide in CLL. Current status 1800-1830: Anders Österborg Curent status of antibodies for CLL: CD20, CD19, 22, 37, 52, others. 1830-1845: Carsten Niemann Concluding remarks 1900- 3-course seasonal dinner Tilmelding: DHS’ hjemmeside: www.hematology.dk (Søg på CLL meeting i søgefeltet) eller følg Evt. spørgsmål til Conference Coordinator O. Gotthardsen, mail: coordinator@cll-cph.dk Sponsoreret af Roche a/s
CLL2014_Reserver_datoen_Word_DHS.docx